NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Provided By PR Newswire

Last update: Sep 30, 2024

Data Revealed Favorable Safety, Tolerability and Dose-Linear Pharmacokinetics (PK)

Top-Line Data Readout from the MAD Part 2 Expected in the First Quarter of 2025